In vitro toxicity of anti-HIV dideoxynucleosides in human and rat myocytes (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro toxicity of anti-HIV dideoxynucleosides in human and rat myocytes (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 36:A2192 1995. Unique Identifier : AIDSLINE ICDB/95609967
Schmid SM; Coffield RT; Harwell JE; Gordon DG; Osborn BL; Tomaszewski JE; Page JG; Southern Research Inst., Birmingham, AL 35255

Abstract: Chemotherapeutic-induced cardiomyopathy presents significant adverse effects limiting clinical utilization. In an effort to screen potential new agents prior to testing in animal models, we have employed in vitro myocardial assays with myocytes. Rat pup myocytes (Sprague-Dawley and Fisher 344), and a transformed human fetal myocyte line (W1) were prepared in culture and exposed to either NSC 612049 (ddI), NSC 98700 (ddA), NSC 613792 (beta-F-ddA), or NSC 616290 (beta-F-ddI) for 6 hours. Positive control drugs included minoxidil, and doxorubicin (NSC 123127). Toxicity was measured by decreased cell viability (MTT), and extracellular lactate dehydrogenase (LDH) in the culture medium over 72 hr. The toxicity-based relationship of IC50 concentrations at 48 hr post-treatment using MTT was doxorubicin much greater than minoxidil greater than ddA greater than ddI, beta-F-ddA, or beta-F-ddI. Similar LDH release results were observed. Data are presented in a table. The use of in vitro assays for detecting overt myocardiotoxic effects may guide in vivo evaluations to determine drug-induced myocardial toxicity.
Keywords: Animal Antiviral Agents/*TOXICITY Cell Line, Transformed Cell Survival/*DRUG EFFECTS Comparative Study Dideoxynucleosides/*TOXICITY Dose-Response Relationship, Drug Female Human HIV/*DRUG EFFECTS Male Myocardium/*CYTOLOGY Rats Rats, Inbred F344 Rats, Sprague-Dawley ABSTRACTKWDanimalantiviralagents/KWDtoxicitycellline,transformedcellsurvival/KWDdrugeffectscomparativestudydideoxynucleosides/KWDtoxicitydose-responserelationship,drugfemalehumanhiv/KWDdrugeffectsmalemyocardium/KWDcytologyratsrats,inbredf344rats,sprague-dawleyabstract
950930
M9591322

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .